AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00765102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
Study NCT00765102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
Study NCT03599817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle promotion program
Description: Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
Study NCT04886843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack
Description: Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
Study NCT04886843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: NMES was applied to the nonaffected side ankle dorsiflexors
Study NCT04886843 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NMES
Description: NMES was applied to the nonaffected side ankle dorsiflexors
Study NCT00660244 — intervention group
Intervention type: DRUG
Intervention: anastrozole
Description: Oral
Study NCT00594165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
Study NCT04749485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
Study NCT02930772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)
Study NCT01270568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
Study NCT01270568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response
Description: Daily practice of relaxation response, reviewed on a weekly basis
Study NCT01270568 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Recollection
Description: Subjects record daily events on a weekly basis for 8 weeks
Study NCT01057706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chiropractic
Description: spinal manipulation and mobilization
Study NCT01057706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic
Description: spinal manipulation and mobilization
Study NCT01057706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: strengthening, stretching, balance
Study NCT01057706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: strengthening, stretching, balance
Study NCT01780519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam
Study NCT02360241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Use of the robot to locate the fictional needle
Study NCT04434339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine
Study NCT04434339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis block
Description: A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
Study NCT03550495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatry involvement
Description: See arm description.
Study NCT02845908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin plus Leucovorin plus 5-FU
Study NCT02845908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin plus Leucovorin plus 5-FU
Study NCT02845908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally PAC
Study NCT02913677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
Study NCT02913677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutrition
Description: Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
Study NCT03745651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.
Study NCT01437436 — intervention group
Intervention type: PROCEDURE
Intervention: ventilation tube
Description: ventilation tube insertion
Study NCT03719469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Green tea group
Study NCT02239731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDX104 (4% Doxycycline)
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Study NCT02239731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FDX104 (4% Doxycycline)
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Study NCT02462590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. rhamnosus GG - Probiotic
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
Study NCT02462590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Microcrystalline Cellulose
Description: Microcrystalline Cellulose
Study NCT03004651 — intervention group
Intervention type: OTHER
Intervention: Power Doppler ultrasound
Description: Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
Study NCT02845908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally PAC
Study NCT03745651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Ruxolitinib matching vehicle cream.
Study NCT02280603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001C
Description: 1ml by topical application twice a day
Study NCT02280603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% minoxidil
Description: 1ml by topical application twice a day
Study NCT03797534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dose regime
Description: The initial dose of the experimental group will be calculated by the Bayesian model.
Study NCT02504632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test
Description: Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates.
Study NCT02504632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
Study NCT03004651 — intervention group
Intervention type: OTHER
Intervention: Clinical evaluation
Description: swollen joint count (SJC) as componant of SDAI
Study NCT04614389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast-enhanced ultrasound
Description: Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
Study NCT04614389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shear Wave Elastography
Description: Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
Study NCT04614389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sequoia System
Description: UltraSound System Cleared by FDA 510 (k) K180067
Study NCT03836287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Active
Study NCT03836287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study NCT03732287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Anesthesia
Description: Application of cooling anesthesia device prior to intravitreal injection
Study NCT02271334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A006 DPI
Description: Single dose 110 mcg, 1 inhalation
Study NCT02271334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A006 DPI
Description: Single dose 220 mcg, 1 inhalation
Study NCT02370654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Study NCT02370654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Study NCT00658346 — intervention group
Intervention type: DRUG
Intervention: Treatment initiation for HIV-1 group O infected patients
Description: The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
Study NCT02820935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT02271334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 1 inhalation
Study NCT02271334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 2 inhalations
Study NCT03984500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
Study NCT03456102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
Study NCT01171144 — intervention group
Intervention type: OTHER
Intervention: Epidemiologic Surveillance System of the Ministry of Health of Panama
Description: Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
Study NCT02820935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT00123305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Study NCT00658346 — intervention group
Intervention type: DRUG
Intervention: Treatment initiation for HIV-1 group M infected patients
Description: The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
Study NCT04159688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol Challenge
Study NCT01171144 — intervention group
Intervention type: OTHER
Intervention: Mortality database of the Contraloria General de la Republica
Description: Reviewing the Mortality database of the Contraloria General de la Republica
Study NCT01171144 — intervention group
Intervention type: OTHER
Intervention: Hospital discharge records
Description: Reviewing the hospital discharge records
Study NCT03661853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 60 minute psycho-education on alcohol and drugs.
Study NCT03661853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Analysis
Description: Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use.
Study NCT03661853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
Study NCT03661853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dealing With Cravings
Description: DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
Study NCT00123305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microplasmin
Description: 1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
Study NCT03836365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling office visit
Description: All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
Study NCT03836365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling phone call
Description: All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
Study NCT01560520 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Observation only
Study NCT02709122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThoraQuik atraumatic set for pneumothorax decompression
Description: pneumothorax decompression in case it is found in accordance with the actually recommendations
Study NCT01899976 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: X-Suit NIR Covered Biliary Stent
Study NCT03608696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine 0.075 mg/ml solution
Study NCT01002131 — intervention group
Intervention type: DEVICE
Intervention: CBCT
Description: Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
Study NCT03804931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
Study NCT03804931 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Infusion of Saline
Description: Infusion of Saline
Study NCT03804931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone
Study NCT03804931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone
Study NCT03804931 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone
Study NCT02688816 — intervention group
Intervention type: DEVICE
Intervention: Xpert HPV
Description: Point-of-care HPV DNA PCR test
Study NCT01242527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 capsules (1g) daily for 12 weeks
Study NCT01242527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 2 capsules (1g) + 2 placebo daily for 12 weeks
Study NCT01242527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 3 capsules (1g) + 1 placebo daily for 12 weeks
Study NCT01242527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 capsules (1g)daily for 12 weeks
Study NCT02256462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
Study NCT01990053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
Study NCT04345848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Two different doses of anticoagulation
Study NCT04345848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Two different doses of anticoagulation
Study NCT03719066 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: killed whole cell oral cholera vaccine
Description: two week interval
Study NCT03719066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed whole cell oral cholera vaccine
Description: two week interval
Study NCT03832569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
Study NCT00124501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Description: 10 sessions BART
Study NCT00124501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback-assisted relaxation training
Description: 10 sessions BART
Study NCT02688816 — intervention group
Intervention type: DEVICE
Intervention: OncoE6
Description: Point-of-care E6 oncoprotein test
Study NCT03132116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Study NCT03132116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).